Clinical trials
Immunity clinical trials
Below are recruiting immunity clinical trials, each written for real people, not researchers. We’re tracking 1,022 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT01780168Recruiting
Study of metabolism, infection, and immunity in mitochondrial disease
This study looks at how metabolism, infections, and the immune system work together in people with mitochondrial disease. It aims to learn more about the condition and may help guide future treatments.
Bethesda, MarylandAges 4 weeks–115 years - NCT06860542RecruitingPhase 2
Inhaled steroid to prevent lung inflammation from returning after immunotherapy
This trial tests whether using an inhaled steroid (budesonide) can help prevent lung inflammation (pneumonitis) from coming back in people who have had it caused by immunotherapy cancer treatment. It may be an option for patients who need extra support after their first bout of this side effect.
Calgary, AlbertaAges 18 years+ - NCT07572864RecruitingPhase 2
Immunotherapy and vaccine before surgery for head and neck cancer
This trial tests a new combination of immunotherapy (a drug that helps your immune system fight cancer) and a mitochondrial vaccine given before surgery for head and neck squamous cell carcinoma. The goal is to help reduce cancer recurrence and improve survival after surgery.
Chengdu, SichuanAges 18 years+ - NCT06980480RecruitingPhase 3
Gammagard to prevent infections in multiple myeloma
This study tests if adding Gammagard (a type of antibody therapy) to your multiple myeloma treatment with Tecvayli can help prevent serious infections. You may qualify if you recently started Tecvayli and are still responding to it.
Mobile, AlabamaAges 18 years+ - NCT06733935RecruitingPhase 1/Phase 2
Study of NKX019 for immune diseases
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
Orange, CaliforniaAges 18–75 - NCT05390515RecruitingPhase 4
Study immune response in adults with psoriasis on tildrakizumab
This trial studies how the immune system responds in adults with moderate-to-severe psoriasis when receiving tildrakizumab. The goal is to better understand treatment effects and immune changes, which may help improve care for people with psoriasis.
San Francisco, CaliforniaAges 18–75 - NCT04416191Recruiting
Immune cells study during inactivity and recovery
This study looks at how your immune system changes when you are inactive and then become more active again. It may help researchers understand how recovery affects immune health after disuse.
Salt Lake City, UtahAges 18–85 - NCT07750171Recruiting
How smoking affects healing around dental implants
This study looks at how smoking affects the body's immune response around dental implants that are healthy or have mild gum disease. It may help us understand why some implants develop problems and could lead to better care for smokers with implants.
Ankara, AnkaraAges 21–75 - NCT07569029RecruitingPhase 1
HIV vaccine with treatment break to boost immune response
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
Birmingham, AlabamaAges 18–60 - NCT07068126Recruiting
New treatment for kids with lasting ITP
This trial tests a new approach for children ages 1 to 10 who have had ITP for 3–12 months. It aims to find a better way to manage the condition and improve platelet counts.
AsyutAges 1–10 - NCT06946745Recruiting
Studying IBI363 combo for advanced colorectal cancer
This study tests a new combination therapy (IBI363 with other drugs) for advanced colorectal cancer that is pMMR/MSI-L/MSS. It aims to understand how the immune system around the tumor changes during treatment.
BeijingAges 18–75 - NCT06988592Recruiting
Chemo plus immunotherapy for advanced bile duct cancer
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) plus an immunotherapy drug (PD-1/PD-L1 inhibitor) as the first treatment for advanced bile duct or gallbladder cancer. It aims to see if this combination works better and to understand how the immune system responds.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06844110Recruiting
New PET scan for cancer using CD73 probe
This trial tests a new PET imaging agent that targets CD73, a protein found on many cancer cells. It may help doctors see tumors more clearly without chemotherapy or radiation before the scan.
Dongcheng, Beijing MunicipalityAges 18–70 - NCT06562777Recruiting
How symptoms differ between men and women during immunotherapy
This study looks at how symptoms during immunotherapy (a cancer treatment that boosts your immune system) may differ between men and women. Researchers will follow people with cancer who are starting immunotherapy to see if men and women report different side effects.
Portland, OregonAges 18 years+ - NCT06519487Enrolling by invitation
How social experiences affect immune cells
This study looks at how social experiences and background may influence immune cell activity. It could help understand why some groups have different health outcomes.
Baltimore, MarylandAges 18 years+ - NCT06463119Recruiting
Vaccine response registry for immune-weakened patients
This study creates a registry to track how people with weakened immune systems respond to vaccines. It helps doctors better understand which vaccines work best for patients like you.
GenevaAges Any age - NCT06286644Recruiting
Hops compounds and your immune system
This study looks at how compounds found in hops (used in beer) affect your immune system. If you are a healthy adult, you may join and help researchers learn more about how these natural substances work.
ViennaAges 18–70 - NCT06209736RecruitingPhase 2
Study of OMS906 for C3G and ICGN kidney diseases
This study tests an experimental drug called OMS906 for people with C3G or ICGN (immune-related kidney diseases). It aims to see if the drug is safe and can reduce kidney damage. You may qualify if you have a confirmed diagnosis, high protein in your urine, and stable kidney function.
KaunasAges 18–99 - NCT05937295RecruitingPhase 1
Peptide vaccine plus immunotherapy for a specific cancer gene fusion
This Phase 1 study tests a custom vaccine made to match a specific cancer genetic change (DNAJB1-PRKACA fusion). It’s combined with an approved immunotherapy (immune checkpoint inhibitor) to help your immune system recognize and fight the cancer. You may be considered if your cancer is advanced or has spread and you meet several blood/organ and health requirements.
Tübingen, Baden-WürtembergAges 18 years+ - NCT05820802Recruiting
Studying immune cells in children during surgery
This study looks closely at immune cells in children while they are having surgery under general anesthesia using a specific muscle-relaxing medicine (rocuronium). It may help researchers understand how immune systems respond around the time of surgery and anesthesia.
SeoulAges 2–18 - NCT05664035Recruiting
Measuring infection patterns in adults with frequent respiratory infections
This study looks at how often “SPAD” happens in adults who get repeated bacterial infections in the chest or sinuses. It aims to better understand your infection frequency and related immune test results, which may help guide future care.
LilleAges 18–65 - NCT05858632RecruitingPhase 4
Study immune patterns during guselkumab skin response in psoriasis
This trial studies how the immune system changes in the skin after guselkumab treatment for psoriasis, including the scalp. You may be asked to meet certain scalp severity and medication safety rules.
San Francisco, CaliforniaAges 18 years+ - NCT05749627Recruiting
Vaccine for advanced cancers using your tumor’s targets
This trial tests a personalized vaccine made from “neoantigens” (tumor-specific targets) to help your immune system fight advanced, inoperable solid tumors. It may be an option if standard treatment didn’t work or you stopped it and your health is strong enough for trial treatment.
Nanchang, JiangxiAges 18–70 - NCT05732779Recruiting
App-based check-ins to help teens take transplant medicines
This study tests a phone app that uses video check-ins (called directly observed therapy) to help adolescent heart-transplant patients take their immunosuppression medicines as prescribed. It may help reduce missed doses, which is important for protecting the transplanted heart.
Coral Gables, FloridaAges 10–21
Hear when a new Immunity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunity?
- Yes. Clin2 currently lists 1,022 recruiting immunity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.